Respiratory Syncytial Virus – pharmaceutical daily

September 3, 2019 Off

Janssen nets FDA’s Breakthrough Therapy Designation for investigational prophylactic vaccine for the prevention of respiratory syncytial virus in older adults

The Janssen Pharmaceutical Companies of Johnson & Johnson got the FDA’s Breakthrough Therapy Designation for its investigational prophylactic vaccine for the prevention of #respiratory syncytial virus (RSV)- mediated lower respiratory tract disease in adults aged 60 years or older. @JNJNews

April 8, 2019 Off

ReViral Announces Grant of Key US Composition of Matter Patent for Their Respiratory Syncytial Virus Inhibitor Programme

By BusinessWire

Patent claims RSV fusion protein inhibitors as medicines including lead pipeline candidate, RV521; patent nominally expires in 2035 (unextended) The…

November 9, 2017 Off

BN kicks off phase 2 study of RS virus vaccine, plans on human study next year

By Dino Mustafić

Bavarian Nordic has started the Phase 2 extension study of MVA-BN RSV, a universal vaccine candidate designed to elicit a broad…

March 3, 2017 Off

Sanofi, AstraZeneca making Respiratory Syncytial Virus vaccine

By Dino Mustafić

Sanofi’s vaccines global business unit Sanofi Pasteur has signed a deal with AstraZeneca’s biologics bramch MedImmune, to make and sell a monoclonal antibody-called MEDI8897-for the prevention of the most common reason for lower respiratory tract infections in newborns and infants, Respiratory Syncytial Virus (RSV).